Quick Answer
PTC THERAPEUTICS, INC. reported R&D Expense of $455.25 million for fiscal year 2025.
PTC THERAPEUTICS, INC. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $455.25M | -14.8% |
| 2024 | $534.48M | -19.8% |
| 2023 | $666.56M | +2.3% |
| 2022 | $651.50M | +20.5% |
| 2021 | $540.68M | +13.2% |
| 2020 | $477.64M | +85.5% |
| 2019 | $257.45M | +49.7% |
| 2018 | $171.98M | +46.4% |
| 2017 | $117.46M | -0.2% |
| 2016 | $117.63M | -3.4% |
| 2015 | $121.82M | +52.6% |
| 2014 | $79.84M | +45.5% |
| 2013 | $54.88M | +18.9% |
| 2012 | $46.14M | -21.4% |
| 2011 | $58.68M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $100.16M | -37.9% | -11.4% |
| June 30, 2025 | $112.99M | -14.5% | +3.7% |
| March 31, 2025 | $108.97M | -6.2% | -32.5% |
| September 30, 2024 | $161.41M | -1.7% | +22.1% |
| June 30, 2024 | $132.17M | -28.9% | +13.8% |
| March 31, 2024 | $116.13M | -40.5% | -29.3% |
| September 30, 2023 | $164.21M | -0.8% | -11.7% |
| June 30, 2023 | $185.87M | +18.2% | -4.7% |
- PTC THERAPEUTICS, INC. showed a decrease of -14.8% in R&D Expense compared to the prior fiscal year.
- Over the 2011–2025 period, PTC THERAPEUTICS, INC.’s r&d expense has grown by 675.9% (from $58.68 million to $455.25 million).
- The most recent figure is from PTC THERAPEUTICS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: